Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers

American Heart Journal
Juhana KarhaDeepak L Bhatt

Abstract

Aspirin inhibits platelet aggregation and is widely used in the treatment of cardiovascular disease. Some individuals are less responsive to aspirin's antiplatelet effect, a phenomenon termed aspirin resistance. It is not known whether the antiplatelet effect is fully preserved with the enteric-coated (EC) formulation. We performed a prospective randomized trial of 50 healthy volunteers using a crossover design to compare the EC with the standard aspirin formulations. The subjects received a 7-day course of each aspirin formulation (81-mg) (Bayer Corporation, Morristown, NJ) separated by a 3-week washout period. Platelet function was measured before and after each course using optical aggregometry (with arachidonic acid and adenosine diphosphate as agonists) and a point-of-care platelet assay. The assays were reproducible, and the variation in baseline platelet function was small to moderate between the subjects. There was no difference in the extent of platelet inhibition between the EC and standard formulations with any of the 3 assays. With the point-of-care platelet assay, the mean aspirin effect favoring the standard formulation (more aggregation inhibition) compared with the EC formulation was 1.6% +/- 15.8% (P = .60 for ...Continue Reading

References

Dec 1, 1977·Australian and New Zealand Journal of Medicine·G B HoweG G Graham
Jul 1, 1991·British Journal of Clinical Pharmacology·A B HawthorneC J Hawkey
Dec 1, 1985·Circulation·C PatronoL Forni
Apr 2, 1999·Alimentary Pharmacology & Therapeutics·A T ColeS Heptinstall
Sep 1, 1999·Alimentary Pharmacology & Therapeutics·H G DammannN Wolf
Aug 29, 2002·Alimentary Pharmacology & Therapeutics·A Van HeckenJ N De Hoon
Jan 2, 2003·Nature Reviews. Drug Discovery·Deepak L Bhatt, Eric J Topol
Jul 23, 2003·Circulation·Eric J TopolUNKNOWN Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators
Dec 13, 2003·Stroke; a Journal of Cerebral Circulation·Mark J AlbertsJun Teruya
Dec 17, 2003·The American Journal of Cardiology·John C WangDaniel I Simon
Mar 19, 2004·Journal of the American College of Cardiology·Deepak L Bhatt
Aug 17, 2004·American Heart Journal·Deepak L BhattUNKNOWN Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee
Dec 18, 2004·Stroke; a Journal of Cerebral Circulation·Rocio Gonzalez-ConejeroVincente Vicente

❮ Previous
Next ❯

Citations

Dec 18, 2013·British Journal of Anaesthesia·A D Oprea, W M Popescu
Jan 20, 2010·Journal of Postgraduate Medicine·V S ThomsonJ Jose
Sep 3, 2013·Pharmacology & Therapeutics·Christopher N Floyd, Albert Ferro
May 24, 2008·Thrombosis Research·Helle L NielsenAnne-Mette Hvas
Jan 24, 2007·Thrombosis Research·Huyen A TranJohn W Eikelboom
Jul 3, 2007·The American Journal of Medicine·Wai-Hong ChenChu-Pak Lau
Jan 2, 2007·The American Journal of Cardiology·Eli I LevNeal S Kleiman
Mar 29, 2008·Journal of Vascular Surgery·Thomas F RehringUNKNOWN Society for Vascular Surgery
Sep 21, 2018·Journal of Human Hypertension·Renuka ShanmugalingamAngela Makris
Apr 22, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeremiah P Depta, Deepak L Bhatt
Apr 14, 2012·Blood·Ayalew Tefferi
Mar 13, 2021·The American Journal of Cardiology·Deepak L Bhatt, Charles V Pollack
Jun 16, 2021·Seminars in Thrombosis and Hemostasis·Mikael ChristiansenAnne-Mette Hvas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.